Royal Society of Chemistry Welcomes New President
on 9 July. Professor Tildesley takes over from Professor Lesley Yellowlees, who becomes Immediate Past-President.
Professor Tildesley is a world-leading expert in large-scale computational modelling and simulation, with a wealth of experience across both academia and industry. He is currently Director of the European Center for Atomic and Molecular Computation (CECAM) at the École Polytechnique Fédérale de Lausanne in Switzerland. He is also co-chair on the UK e-Infrastructure Leadership Group.
Professor Dominic Tildesley. Picture Credit: David Parry/PA courtesy of the Royal Society of Chemistry
The Royal Society of Chemistry welcomed Professor Dominic Tildesley as its new president at the Annual General Meeting
His wide-ranging career has taken him from academic research in the US to lectureships in the UK, to senior positions in research and development at fast moving consumer goods giant Unilever, and back to academia at CECAM, where his role is to promote research into applying powerful computational methods to problems across science and technology.
During his time in office, Professor Tildesley intends to apply his academic and industrial experience to work with the Royal Society of Chemistry to expand its support for the chemical
sciences industry and to forge stronger collaborations between industry and academia.
He also intends to follow firmly in the footsteps of his predecessor by continuing to champion diversity in the chemical sciences.
The Royal Society of Chemistry’s Chief Executive, Dr Robert Parker, said: “We are delighted to welcome Dominic as our President. He is a valued member of our Council and brings to the role a vast amount of knowledge and experience of interdisciplinary research across chemistry, materials science, life sciences and engineering in both university and industrial environments.
“We are very much looking forward to drawing on his experience and working with him on initiatives to build our community, bringing chemical scientists together from across all sectors and disciplines to share knowledge and ideas.
30963pr@reply-direct.com Early Access Scheme in Global Spotlight at BIO
A UK Innovation Policy which will enable patients to get early access to new therapies was in the spotlight at the world’s largest biotech convention in San Diego, California, (23-26 June).
Speaking at a policy session on the UK’s new Early Access to Medicines Scheme at the BIO International Convention in San Diego, Dr Ian Hudson, Chief Executive of the Medicines and Healthcare products Regulatory Agency (MHRA), explained the scheme and encouraged companies from around the globe to consider the UK as a great place to research and develop new therapies.
Dr Hudson said: “The Early Access to Medicines Scheme offers the opportunity for patients with life threatening or seriously debilitating conditions where there are inadequate treatment options to receive promising new medicines ahead of their formal licensing process.
“MHRA is keen to support the development of novel innovative medicines and the recent integration of NIBSC, the National Institute for Biological Standards and Control, strengthens our ability to provide advice and support to those developing new biologics”
Steve Bates, Chief Executive of the BioIndustry Association (BIA), who chaired the session said: “The BIA has long championed regulatory modernisation to keep pace with emerging science. Today’s session shows that UK innovation in access to medicine and the UK life sciences strategy is on the global map. The Early Access Scheme is just one part of the UK strategy for life sciences which is getting the UK noticed on the global stage as a key location for drug discovery and development.”
Exhibition Floor at the BIO International Convention in San Diego
“One of the facets that makes the UK an unrivalled ecosystem that brings together businesses, researchers, clinicians and patients to translate discovery into clinical use is our leading health regulation and health economics capacity in the MHRA and NICE.
“Having global bio-pharma investors meet first hand with UK regulators and see Ian’s commitment to excellence and the MHRA’s desire to be globally relevant and enablers to new science makes a material difference.“
31036pr@reply-direct.com
AstraZeneca Reveals Designs for new Centre in Cambridge
AstraZeneca has revealed proposed designs for its new Global R&D Centre and Corporate Headquarters in Cambridge which will be located on the Cambridge Biomedical Campus (CBC). The Global Centre will incorporate an R&D Enabling Building and an Energy Centre which will support the whole facility with energy and IT infrastructures.
Key features of the site include technology labs with glass walls to promote ‘visible science’, ensuring scientific innovation is the primary focus for all staff, both in R&D and other functions and a number of open spaces and thoroughfares to encourage collaboration not only within AstraZeneca, but also with the wider scientific community within the CBC and beyond.
The site will also be low rise including a central courtyard reflecting the unique architecture of the colleges of Cambridge University and the company is seeking Building Research Establishment Environmental
Assessment Methodology
(BREAAM) Excellent status for the site. It will feature labs that represent best practice in low energy design and the largest ground source heat pump in Europe. “Green Roofs” will also be installed across the majority of the site.
Mene Pangalos, Executive Vice President, Innovative Medicines & Early Development at AstraZeneca said: “We are very excited to be able to reveal the plans for our new site in Cambridge today, (July 18). Our aim is to create an open, welcoming and vibrant centre that will inspire our teams and partners to push the boundaries of scientific innovation.
”The new site will bring together AstraZeneca’s small molecule and biologics research and development activity, opening up opportunities to exploit the promise of biologics and small molecule combinations. The CBC will be the new UK home for biologics research and protein engineering carried out by MedImmune, AstraZeneca’s biologics arm. MedImmune already employs around 500 people at Granta
Park, to the south east of the city.
“With our combined AstraZeneca and MedImmune portfolios we are already uniquely positioned to explore the promise of combination therapies in transforming the way patients are treated,” said Dr Bahija Jallal, Executive Vice President, MedImmune. “Our new Global Research Centre in Cambridge will see AstraZeneca and MedImmune scientists working side by side to advance science in our core therapeutic areas. This will support and strengthen our focus on combining the expertise across our business to develop new ways to treat patients and tackle the significant unmet need that exists in areas such as oncology.
Herzog & de Meuron, are the architects selected to design the new site; building works are expected to start early next year with the new site coming online in late 2016.
31046pr@reply-direct.com
To be included in our next issue, send all your Business and Financial News stories to
heather@intlabmate.com
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32
